Dr. Sujith R. Kalmadi, MD
Hematology & Oncology (Hematology & Oncology Physician)
695 S Dobson Rd
Chandler, AZ 85224
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 833
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
AZ license 38208
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Chandler Regional Medical Center Chandler, AZ
- Yavapai Regional Medical Center Prescott, AZ
- Banner Desert Medical Center Mesa, AZ
- Mercy Gilbert Medical Center Gilbert, AZ
- Banner Baywood Medical Center Mesa, AZ
Medical groups
- Ironwood Physicians PC (116 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 833
- Services billed
- 305,505
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 48,480 | 19 |
| Injection, nivolumab, 1 mg | 33,902 | 12 |
| Injection, ferric carboxymaltose, 1 mg | 24,750 | 16 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 19,675 | 157 |
| Injection, fosaprepitant, 1 mg | 16,500 | 21 |
| Injection, pembrolizumab, 1 mg | 15,900 | 12 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 5,170 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 3,656 | 51 |
| Injection, denosumab, 1 mg | 3,300 | 12 |
| Injection, palonosetron hcl, 25 mcg | 2,770 | 42 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Chandler, AZ | 207 |
| Pantoprazole Sodium Other prescribers in Chandler, AZ | 118 |
| Abiraterone Acetate | 112 |
| Prednisone Other prescribers in Chandler, AZ | 107 |
| Prochlorperazine Maleate Other prescribers in Chandler, AZ | 92 |
| Gabapentin Other prescribers in Chandler, AZ | 84 |
| Ondansetron Odt (ondansetron) Other prescribers in Chandler, AZ | 80 |
| Dexamethasone Other prescribers in Chandler, AZ | 76 |
| Eliquis (apixaban) Other prescribers in Chandler, AZ | 72 |
| Letrozole Other prescribers in Chandler, AZ | 72 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 46 companies reported 298 payments worth $100,541 in total to this clinician.
| Janssen Biotech, Inc. | $31,437 |
|---|---|
| Beone Medicines USA, Inc. | $15,252 |
| Beigene USA, Inc. | $12,861 |
| Takeda Pharmaceuticals U.S.A., Inc. | $11,098 |
| Bayer HealthCare Pharmaceuticals Inc. | $9,107 |
| Genentech USA, Inc. | $5,808 |
| E.r. Squibb & Sons, L.l.c. | $3,956 |
| Onmark, Inc. | $2,933 |
| Compensation for services other than consulting (speaking, faculty) | $67,822 |
|---|---|
| Consulting Fee | $13,369 |
| Travel and Lodging | $11,847 |
| Food and Beverage | $7,384 |
| Education | $99.95 |
| Gift | $19.74 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Jan 30, 2025 | Compensation for services other than consulting (speaking, faculty) ALUNBRIG · ONCOLOGY | $8,350 |
| Genentech USA, Inc. Oct 10, 2025 | Consulting Fee Tecentriq; Phesgo · BioOncology | $4,579 |
| Beone Medicines USA, Inc. Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $4,400 |
| Beone Medicines USA, Inc. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $4,400 |
| Beigene USA, Inc. Feb 14, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $4,400 |
| Janssen Biotech, Inc. Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Feb 6, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,125 |
| Bayer HealthCare Pharmaceuticals Inc. Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) Nubeqa · Oncology | $3,959 |
All 54 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Dec 11, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Green Valley, AZ · in-kind | $619 |
| Geron Corporation Dec 4, 2025 | Consulting Fee RYTELO · MYELODYSPLASTIC SYNDROME | $1,200 |
| Genmab U.S., Inc. Nov 14, 2025 | Travel and Lodging Epkinly · Oncology · travel to Nashville, TN · in-kind | $1,122 |
| Genmab U.S., Inc. Nov 14, 2025 | Travel and Lodging Epkinly · Oncology · travel to Nashville, TN · in-kind | $363 |
| Beone Medicines USA, Inc. Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $4,400 |
| Janssen Biotech, Inc. Nov 12, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Green Valley, AZ · in-kind | $5.50 |
| Beone Medicines USA, Inc. Nov 10, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Temple City, CA · in-kind | $371 |
| Beone Medicines USA, Inc. Nov 10, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Temple City, CA · in-kind | $205 |
| Beone Medicines USA, Inc. Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $1,650 |
| Onmark, Inc. Nov 3, 2025 | Travel and Lodging travel to Irving, TX | $893 |
| Onmark, Inc. Nov 3, 2025 | Travel and Lodging travel to Irving, TX | $310 |
| Onmark, Inc. Nov 3, 2025 | Travel and Lodging travel to Irving, TX | $271 |
| Onmark, Inc. Nov 3, 2025 | Gift | $19.74 |
| Beone Medicines USA, Inc. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $4,400 |
| Beone Medicines USA, Inc. Oct 29, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Tucson, AZ · in-kind | $707 |
| Genentech USA, Inc. Oct 10, 2025 | Consulting Fee Tecentriq; Phesgo · BioOncology | $4,579 |
| Genentech USA, Inc. Oct 10, 2025 | Travel and Lodging Tecentriq; Phesgo · BioOncology · travel to San Francisco, CA · in-kind | $513 |
| Genentech USA, Inc. Oct 10, 2025 | Travel and Lodging Tecentriq; Phesgo · BioOncology · travel to San Francisco, CA · in-kind | $357 |
| Janssen Biotech, Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Oct 8, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Colorado Springs, CO · in-kind | $654 |
| Janssen Biotech, Inc. Sep 12, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Colorado Springs, CO · in-kind | $5.50 |
| Janssen Biotech, Inc. Sep 10, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Colorado Springs, CO · in-kind | $286 |
| Janssen Biotech, Inc. Aug 29, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,608 |
| Janssen Biotech, Inc. Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Aug 20, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Tucson, AZ · in-kind | $665 |
| E.r. Squibb & Sons, L.l.c. Jul 24, 2025 | Consulting Fee | $518 |
| E.r. Squibb & Sons, L.l.c. Jul 22, 2025 | Consulting Fee | $518 |
| E.r. Squibb & Sons, L.l.c. Jul 22, 2025 | Consulting Fee | $518 |
| E.r. Squibb & Sons, L.l.c. Jul 22, 2025 | Consulting Fee | $518 |
| E.r. Squibb & Sons, L.l.c. Jul 22, 2025 | Consulting Fee | $518 |
| E.r. Squibb & Sons, L.l.c. Jul 18, 2025 | Consulting Fee | $1,150 |
| Janssen Biotech, Inc. Jun 19, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Tucson, AZ · in-kind | $5.50 |
| Bayer HealthCare Pharmaceuticals Inc. Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) Nubeqa · Oncology | $3,959 |
| Bayer HealthCare Pharmaceuticals Inc. Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) Nubeqa · Oncology | $3,350 |
| Bayer HealthCare Pharmaceuticals Inc. Apr 8, 2025 | Travel and Lodging Nubeqa · Oncology · travel to Peoria, AZ · in-kind | $613 |
| Bayer HealthCare Pharmaceuticals Inc. Apr 5, 2025 | Travel and Lodging Nubeqa · Oncology · travel to Prescott, AZ · in-kind | $1,065 |
| Beone Medicines USA, Inc. Apr 4, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $3,300 |
| Janssen Biotech, Inc. Mar 24, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,608 |
| AstraZeneca Pharmaceuticals LP Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $1,640 |
| Beigene USA, Inc. Feb 14, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $4,400 |
| Beigene USA, Inc. Feb 14, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to San Gabriel, CA · in-kind | $433 |
| Beigene USA, Inc. Feb 14, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to San Gabriel, CA · in-kind | $343 |
| Beigene USA, Inc. Feb 14, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to San Gabriel, CA · in-kind | $260 |
| Janssen Biotech, Inc. Feb 6, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,125 |
| Beigene USA, Inc. Feb 6, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $3,300 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 6, 2025 | Compensation for services other than consulting (speaking, faculty) ALUNBRIG · ONCOLOGY | $1,670 |
| Takeda Pharmaceuticals U.S.A., Inc. Jan 30, 2025 | Compensation for services other than consulting (speaking, faculty) ALUNBRIG · ONCOLOGY | $8,350 |
| Janssen Biotech, Inc. Jan 29, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Green Valley, AZ · in-kind | $874 |
| Beigene USA, Inc. Jan 27, 2025 | Consulting Fee | $3,850 |
| Janssen Biotech, Inc. Jan 27, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,575 |
| Takeda Pharmaceuticals U.S.A., Inc. Jan 20, 2025 | Travel and Lodging ALUNBRIG · ONCOLOGY · travel to COSTA MESA, CA · in-kind | $899 |
| Janssen Biotech, Inc. Jan 15, 2025 | Education DARZALEX · Oncology · in-kind | $99.95 |
| Janssen Biotech, Inc. Jan 6, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Green Valley, AZ · in-kind | $5.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 5 companies. The companies reported $1,284,150 in research payments for these studies, mostly to the institutions running them.
- CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine …
AstraZeneca UK Limited - Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Daiichi Sankyo Inc. · Active, not recruiting · NCT05555732 - This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab MEDI4736 and domvanalimab AB154 compared with durvalumab plus placebo…
AstraZeneca Pharmaceuticals LP - Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Daiichi Sankyo Inc. · Active, not recruiting · NCT05215340 - A phase 2 basket study of disitamab vedotin in adult subjects with previously treated locallyadvanced unresectable or metastatic solid tumors that express HER2
Pfizer Inc. - Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
Daiichi Sankyo Inc. · Active, not recruiting · NCT04656652 - Phase III Ipatasertib plus abiraterone in mCRPC 1st Line
Genentech, Inc. - A phase 3 randomized doubleblind placebocontrolled study of talazoparib with enzalutamide in metastatic castrationresistant prostate cancer
Pfizer Inc. - A randomized openlabel phase 3 trial of tisotumab vedotin vs investigators choice chemotherapy in second or thirdline recurrent or metastatic cervical cancer
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.